Combined bronchodilators (tiotropium plus olodaterol) for patients with chronic obstructive pulmonary disease

LAUR Repository

Show simple item record

dc.contributor.author Ramadan, Wijdan H.
dc.contributor.author Kabbara, Wissam K.
dc.contributor.author El Khoury, Ghada
dc.contributor.author Al Assir, Sarah A.
dc.date.accessioned 2016-09-29T07:42:41Z
dc.date.available 2016-09-29T07:42:41Z
dc.date.copyright 2015 en_US
dc.date.issued 2016-09-29
dc.identifier.issn 1176-9106 en_US
dc.identifier.uri http://hdl.handle.net/10725/4446
dc.description.abstract Chronic obstructive pulmonary disease (COPD), a respiratory disease characterized by a progressive decline in lung function, is considered to be a leading cause of morbidity and mortality. Long-acting inhaled bronchodilators, such as long-acting β2 agonists (LABAs) or long-acting muscarinic antagonists (LAMAs), are the cornerstone of maintenance therapy for patients with moderate-to-very-severe COPD. For patients not sufficiently controlled on a single long-acting bronchodilator, a combination of different bronchodilators has shown a significant increase in lung function. Tiotropium, a once-daily dosing LAMA, demonstrated sustained improvements in lung function as well as improved health-related quality of life, reduced exacerbations, and increased survival without altering the rate of decline in the mean forced expiratory volume in 1 second (FEV1) with fairly tolerable side effects. Olodaterol is a once-daily dosing LABA that has proven to be effective in improving lung function, reducing rescue medication use, and improving dyspnea and health-related quality of life, as well as improving exercise endurance with an acceptable safety profile. The combination of olodaterol and tiotropium provided additional improvements in lung function greater than monotherapy with each drug alone. Several well-designed randomized trials confirmed that the synergistic effect of both drugs in combination was able to improve lung function and health-related quality of life without a significant increase in adverse effects. The objective of this paper is to review available evidence on the clinical efficacy and safety of tiotropium, olodaterol, and their combination in patients with COPD. en_US
dc.language.iso en en_US
dc.title Combined bronchodilators (tiotropium plus olodaterol) for patients with chronic obstructive pulmonary disease en_US
dc.type Article en_US
dc.description.version Published en_US
dc.author.school SOP en_US
dc.author.idnumber 200104485 en_US
dc.author.idnumber 200104046 en_US
dc.author.department Pharmacy Practice en_US
dc.description.embargo N/A en_US
dc.relation.journal International Journal of Chronic Obstructive en_US
dc.journal.volume 10 en_US
dc.article.pages 2347-2356 en_US
dc.keywords Chronic obstructive pulmonary disease en_US
dc.keywords Bronchodilator en_US
dc.keywords Long-acting β2 agonists en_US
dc.keywords Long-acting muscarinic antagonist en_US
dc.keywords Olodaterol en_US
dc.keywords Tiotropium en_US
dc.identifier.doi http://dx.doi.org/10.2147/COPD.S88246 en_US
dc.identifier.ctation Ramadan, W. H., Kabbara, W. K., El Khoury, G. M., & Al Assir, S. A. (2015). Combined bronchodilators (tiotropium plus olodaterol) for patients with chronic obstructive pulmonary disease. International journal of chronic obstructive pulmonary disease, 10, 2347. en_US
dc.author.email wissam.kabbara@lau.edu.lb en_US
dc.author.email ghada.khoury@lau.edu.lb en_US
dc.identifier.tou http://libraries.lau.edu.lb/research/laur/terms-of-use/articles.php en_US
dc.identifier.url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4634833/ en_US
dc.orcid.id https://orcid.org/0000-0002-7310-9192 en_US
dc.orcid.id https://orcid.org/0000-0002-7642-4833 en_US

Files in this item

This item appears in the following Collection(s)

Show simple item record

Search LAUR

Advanced Search


My Account